Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective faithfully but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last few shares. My 1st CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing image in the Uptick Newswire job interview which I came away with a poor impression of the business.

Irony of irony, the poor viewpoint of mine of the company has grown steadily, yet the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of the know-how as well as linked intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) as well as the very first brand new drug program approval ($five million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and numerous indications, it has this single treatment as well as a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

Its opening banner on its website (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple publications in addition to multiple delivering presentations.

Might all this be smoke and mirrors? That is a question I have been asking myself with the very start of the interest of mine in this particular company. Judging by way of the multiples of a huge number of various remarks on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or some could say cult stock. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *